Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Boyle

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|September 10, 2018
The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic AntibodiesPeter M Bowers, William J Boyle, Robert Damoiseaux
Annual Review of Immunology|February 28, 2002
RANK-L and RANK: T cells, bone loss, and mammalian evolutionLars E Theill, William J Boyle, Josef M Penninger
Nature|May 16, 2003
Osteoclast differentiation and activationWilliam J Boyle, W Scott Simonet, David L Lacey
Drug Discovery Today|October 27, 2009
Surrogate approaches in development of monoclonal antibodiesGadi Gazit Bornstein, Scott L Klakamp, Laura Andrews, et al.
The Journal of Clinical Investigation|April 17, 2003
Role of RANK ligand in mediating increased bone resorption in early postmenopausal womenGuitty Eghbali-Fatourechi, Sundeep Khosla, Arunik Sanyal, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2021
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switchesHwai Wen Chang, Gerhard Frey, Haizhen Liu, et al.
Arthritis and Rheumatism|December 17, 2002
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritisBrad Bolon, Victoria Shalhoub, Paul J Kostenuik, et al.
Antibody Therapeutics|June 10, 2025
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugateHwai Wen Chang, Jing Wang, Haizhen Liu, et al.
Mabs|April 9, 2025
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugateHwai Wen Chang, Gerhard Frey, Jing Wang, et al.
Mabs|March 6, 2024
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapyGerhard Frey, Ana Paula G Cugnetti, Haizhen Liu, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|September 10, 2018
The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic AntibodiesPeter M Bowers, William J Boyle, Robert Damoiseaux
Annual Review of Immunology|February 28, 2002
RANK-L and RANK: T cells, bone loss, and mammalian evolutionLars E Theill, William J Boyle, Josef M Penninger
Nature|May 16, 2003
Osteoclast differentiation and activationWilliam J Boyle, W Scott Simonet, David L Lacey
Drug Discovery Today|October 27, 2009
Surrogate approaches in development of monoclonal antibodiesGadi Gazit Bornstein, Scott L Klakamp, Laura Andrews, et al.
The Journal of Clinical Investigation|April 17, 2003
Role of RANK ligand in mediating increased bone resorption in early postmenopausal womenGuitty Eghbali-Fatourechi, Sundeep Khosla, Arunik Sanyal, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2021
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switchesHwai Wen Chang, Gerhard Frey, Haizhen Liu, et al.
Arthritis and Rheumatism|December 17, 2002
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritisBrad Bolon, Victoria Shalhoub, Paul J Kostenuik, et al.
Antibody Therapeutics|June 10, 2025
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugateHwai Wen Chang, Jing Wang, Haizhen Liu, et al.
Mabs|April 9, 2025
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugateHwai Wen Chang, Gerhard Frey, Jing Wang, et al.
Mabs|March 6, 2024
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapyGerhard Frey, Ana Paula G Cugnetti, Haizhen Liu, et al.
Pageof 2